AI helps older adults report accurate blood pressure readings at home

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

Florida's plan to drop school vaccine mandates likely won't take effect for 90 days and would include only chickenpox and a few other illnesses unless lawmakers decide to extend it to other diseases, like polio and measles, the health department said Sunday.

New research indicates that many patients who undergo surgery with the intent to cure early‐stage cancer continue or start opioid prescriptions in the year following surgery. The findings are published in Cancer.

Black adolescents with mental distress are less likely to use mental health services than their white peers, and Black girls are the least likely to access care, according to new research published in the Canadian Medical Association Journal.

Canada must enact strong, effective legislation to protect youth from gambling advertising. Minors are suffering harms from problem gambling despite age restrictions, argue authors in an editorial in CMAJ (Canadian Medical Association Journal).

Imagine a game show where the host asks the contestant to randomly pick one option out of three: A, B or C.

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

A first-in-human Phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in patients with relapsed small cell lung cancer (SCLC).

Blood pressure matters at all ages. Children with higher blood pressure at age 7 may be at an increased risk of dying of cardiovascular disease by their mid-50s, according to preliminary research presented at the American Heart Association's Hypertension Scientific Sessions 2025, held in Baltimore, September 4–7, 2025.

Why would a suicidal teenager choose to live? It's not the kind of question most of us ever want to ask. Suicide is the third leading cause of death among 15–29-year-olds worldwide. Much of the research and media coverage still focuses on why teens might want to die. Far less often do we ask the opposite, equally urgent question: what makes life worth holding on to?

Consumption of low- and no-calorie sweeteners (LNCSs) is associated with faster cognitive decline, according to a study published online Sept. 3 in Neurology.

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).

Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ALK+ NSCLC, according to results from the Phase II E4512 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

Zidesamtinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing, demonstrated clinically meaningful activity and durability in patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who had progressed on prior TKI therapy.

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

New results from the ACROSS 2 Phase III trial demonstrate that aumolertinib combined with platinum-pemetrexed chemotherapy significantly improves progression-free survival compared to aumolertinib monotherapy in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor suppressor gene mutations.

When it comes to the future of childhood immunizations, all eyes are on Robert F. Kennedy Jr, US Secretary of Health and Human Services, and his audacious attempt to discredit vaccinations with misinformation and dodgy "science."

Celebrity chef Jamie Oliver has stirred debate by calling the familiar five-a-day message "a lie". Speaking to the Times, he argued that the real health benefits of fruit and vegetables only start to add up at seven, eight or even 11 portions a day.